TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
3.285
-0.245 (-6.94%)
Mar 31, 2025, 3:35 PM EDT - Market open

Company Description

TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms.

The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer.

It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor.

The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December, 2023.

TuHURA Biosciences, Inc. was incorporated in 1993 and is based in Tampa, Florida.TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc. .

TuHURA Biosciences, Inc.
TuHURA Biosciences logo
Country United States
Founded 2009
Industry Biotechnology
Sector Healthcare
Employees 1
CEO James Bianco

Contact Details

Address:
10500 University Center Drive, Suite 110
Tampa, Florida 33612
United States
Phone 813 875 6600
Website tuhurabio.com

Stock Details

Ticker Symbol HURA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001498382
ISIN Number US8989201038
Employer ID 99-0360497
SIC Code 2834

Key Executives

Name Position
Dr. James A. Bianco M.D. President, Chief Executive Officer and Director
Dan Dearborn CPA Executive Vice President of Finance and Chief Financial Officer
Michael Lawman Co-Founder
Patricia Lawman Co-Founder
Michael Krsulich Head of Quality Assurance

Latest SEC Filings

Date Type Title
Mar 18, 2025 8-K Current Report
Mar 12, 2025 8-K Current Report
Feb 14, 2025 8-K Current Report
Feb 7, 2025 S-4 Filing
Jan 3, 2025 8-K Current Report
Dec 23, 2024 S-8 Securities to be offered to employees in employee benefit plans
Dec 12, 2024 425 Filing
Dec 12, 2024 8-K Current Report
Nov 25, 2024 8-K Current Report
Nov 15, 2024 8-K Current Report